Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences:
2024年8月29日，波士頓和聖地亞哥（全球貨幣通訊-半導體）--Rapport Therapeutics, Inc.（納斯達克：RAPP），一家專注於發現和開發針對中樞神經系統（CNS）疾病患者的變革性小分子藥物的臨床階段生物技術公司，今日宣佈管理層將在兩個即將舉行的投資者會議上發表演講：
- The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Thursday, September 5, 2024, at 4:50 pm ET.
- TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on Thursday, September 26, 2024, at 11:40 am ET.
- 摩根士丹利第22屆年度全球醫療健康大會將於2024年9月5日星期四下午4:50在紐約市舉行。
- TD Cowen第4屆年度神經精神疾病新機制峯會（虛擬）將於2024年9月26日星期四上午11:40舉行。
Interested parties may access a live and archived webcast of the Morgan Stanley Conference fireside chat on the "Investors" section of the company's website at: .
有興趣的各方可在公司網站的「投資者」欄目中訪問摩根士丹利大會的現場和存檔網絡視頻。
About Rapport Therapeutics
關於Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system (CNS) disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
Rapport Therapeutics是一家臨床階段的生物技術公司，致力於發現和開發用於治療中樞神經系統(CNS)疾病患者的變革性精準神經藥物。公司的創始人在大腦中與受體相關的蛋白(RAPs)的功能方面有過突破性的發現。他們的發現構成了Rapport的RAP技術平台的基礎，該平台使得可差異化的方法可以生成具有潛在超越傳統神經病學藥物發現許多缺點的精準小分子產品候選物。Rapport的精準神經系統流水線包括公司的主要臨床項目RAP-219，旨在通過其對大腦僅在離散區域表達的RAP的選擇性靶向實現神經解剖學特異性。該公司目前正在推進RAP-219臨床試驗，治療癇性發作、周圍神經病性疼痛和雙相情感障礙。此外，還在進行其他針對CNS疾病的臨床前和後期發現階段計劃，包括慢性疼痛和聽力障礙。
Contact
聯繫人
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
朱莉•迪卡洛
傳播與投資關係負責人
Rapport Therapeutics
jdicarlo@rapportrx.com
Source:
來源：
譯文內容由第三人軟體翻譯。